Please use this identifier to cite or link to this item:
|Title:||AN INVESTIGATION OF RELAXIN-3 B-CHAIN STAPLED PEPTIDES AS NOVEL AGENTS FOR THE TREATMENT OF EATING AND NEUROPSYCHIATRIC DISORDERS||Authors:||SUBHI MARWARI||ORCID iD:||orcid.org/0000-0002-1447-8203||Keywords:||Relaxin-3, RXFP3, Stapled peptide, Intranasal, Anxiety, Depression||Issue Date:||18-Jan-2018||Citation:||SUBHI MARWARI (2018-01-18). AN INVESTIGATION OF RELAXIN-3 B-CHAIN STAPLED PEPTIDES AS NOVEL AGENTS FOR THE TREATMENT OF EATING AND NEUROPSYCHIATRIC DISORDERS. ScholarBank@NUS Repository.||Abstract:||The neuropeptide relaxin-3 plays a crucial role in the normal function of the central nervous system and provides a blueprint for molecular mimicry that can drive drug discovery. However, the development of relaxin-3 peptide therapeutic has been limited with the challenges in synthesis and requirement of surgical implantation into the brain providing the limitation of therapeutic development of novel compounds. Introducing a “hydrocarbon-stapling” technology, we first rationally designed and tested a series of stapled peptides installed at the relaxin-3 B-chain sequence. Notably, the successful emergence of a lead stapled peptide demonstrated improved in-vitro and in-vivo pharmacological activity. Further, we aimed to validate the potential for non-invasive intranasal delivery of relaxin-3 and the lead stapled peptide in animal models. Our research findings have suggested that the strategy of intranasal delivery of “stapled” relaxin-3/RXFP3 system has a potential in pursuit of translational pharmacological approaches for eating and stress-related neuropsychiatric disorders.||URI:||http://scholarbank.nus.edu.sg/handle/10635/141742|
|Appears in Collections:||Ph.D Theses (Open)|
Show full item record
Files in This Item:
|MarwariS.PDF.pdf||7.53 MB||Adobe PDF|
checked on Jul 10, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.